TY  - JOUR
AU  - Sahebi, Firoozeh
AU  - Eikema, Dirk-Jan
AU  - Koster, Linda
AU  - Kroger, Nicolaus
AU  - Meijer, Ellen
AU  - van Doesum, Jaap A
AU  - Rovira, Montserrat
AU  - Koc, Yener
AU  - Angelucci, Emanuele
AU  - Blaise, Didier
AU  - Sammassimo, Simona
AU  - McDonald, Andrew
AU  - Arroyo, Concepcion Herrera
AU  - Sanchez, James F
AU  - Forcade, Edouard
AU  - Castagna, Luca
AU  - Stölzel, Friedrich
AU  - Sanz, Jaime
AU  - Tischer, Johanna
AU  - Ciceri, Fabio
AU  - Valcarcel, David
AU  - Proia, Anna
AU  - Hayden, Patrick J
AU  - Beksac, Meral
AU  - Yakoub-Agha, Ibrahim
AU  - Schönland, Stefan
PY  - 2021
DO  - 10.1016/j.jtct.2021.09.008
UR  - https://hdl.handle.net/10668/25369
T2  - Transplantation and cellular therapy
AB  - Graft-versus-host disease (GVHD) remains among the major causes of treatment failure in patients with multiple myeloma (MM) undergoing allogeneic hematopoietic cell transplantation (allo-HCT). The use of post-transplantation cyclophosphamide (PT-Cy)...
LA  - en
KW  - clinical research
KW  - engraftment
KW  - hematology
KW  - multiple myeloma
KW  - transplantation
KW  - Bone Marrow
KW  - Cyclophosphamide
KW  - Graft vs Host Disease
KW  - Hematopoietic Stem Cell Transplantation
KW  - Humans
KW  - Multiple Myeloma
KW  - Neoplasm Recurrence, Local
KW  - Retrospective Studies
KW  - United States
KW  - Unrelated Donors
TI  - Post-Transplantation Cyclophosphamide for Graft-versus- Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison by Donor Type. A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.
TY  - research article
VL  - 27
ER  -